Ocugen publishes October 2026 investor presentation on gene therapy pipeline
Ocugen furnished an October 2026 investor presentation as Exhibit 99.1 under Regulation FD, which it will post on its website on October 15, 2026. The deck covers clinical programs for OCU400, OCU410ST and OCU410, and reiterates a target of three Biologics License Applications by 2028. The filing contains no reported quarterly financial results, guidance, or new financing, so it gives shareholders updated clinical timelines rather than changes to financial performance.
Key points
- Company will post the presentation on its website on October 15, 2026.
- OCU400 Phase 3 liMeliGhT trial has 140 patients enrolled; topline data expected 1H 2027 and BLA filing targeted for 2Q 2027.
- Company targets three BLAs by 2028 across OCU400, OCU410ST and OCU410.
- Presentation states OCU400 received provisional approval and priority designation from the Bahamas Regulatory Agency for an Early Access Program.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 15, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.